<div id=toc></div>

# Table of Contents

- [q-bio.GN](#q-bio.GN) [Total: 1]
- [q-bio.QM](#q-bio.QM) [Total: 3]
- [q-bio.MN](#q-bio.MN) [Total: 1]
- [cs.AI](#cs.AI) [Total: 1]
- [stat.ME](#stat.ME) [Total: 1]
- [cs.LG](#cs.LG) [Total: 2]
- [stat.AP](#stat.AP) [Total: 1]


<div id='q-bio.GN'></div>

# q-bio.GN [[Back]](#toc)

### [1] [A New Framework for Explainable Rare Cell Identification in Single-Cell Transcriptomics Data](https://arxiv.org/abs/2601.01358)
*Di Su,Kai Ming Ting,Jie Zhang,Xiaorui Zhang,Xinpeng Li*

Main category: q-bio.GN

TL;DR: 提出一个可解释的异常检测框架，用于单细胞转录组数据中的稀有细胞检测，不仅能识别异常细胞，还能提供基于基因的可视化解释。


<details>
  <summary>Details</summary>
Motivation: 当前方法存在三个主要缺陷：1) 异常检测器作为"黑箱"无法解释为何细胞异常；2) 依赖PCA等降维技术将可解释的基因表达数据转化为抽象特征；3) 现有解释算法不适用于单细胞数据的高维、噪声和稀疏特性。

Method: 引入一个可解释的异常检测框架，包含两个关键创新：1) 消除PCA步骤；2) 采用最先进的异常检测器和解释器，有效识别稀有细胞并找到相关基因子空间，为每个稀有细胞及其最接近的正常细胞提供解释。

Result: 该框架不仅能检测单个异常细胞，还能提供基于基因的可视化解释，说明为何某个实例是异常的。

Conclusion: 提出的框架解决了当前方法在单细胞转录组数据中稀有细胞检测的可解释性问题，为疾病发病机制和组织发育动态研究提供了更有效的工具。

Abstract: The detection of rare cell types in single-cell transcriptomics data is crucial for elucidating disease pathogenesis and tissue development dynamics. However, a critical gap that persists in current methods is their inability to provide an explanation based on genes for each cell they have detected as rare. We identify three primary sources of this deficiency. First, the anomaly detectors often function as "black boxes", designed to detect anomalies but unable to explain why a cell is anomalous. Second, the standard analytical framework hinders interpretability by relying on dimensionality reduction techniques, such as Principal Component Analysis (PCA), which transform meaningful gene expression data into abstract, uninterpretable features. Finally, existing explanation algorithms cannot be readily applied to this domain, as single-cell data is characterized by high dimensionality, noise, and substantial sparsity. To overcome these limitations, we introduce a framework for explainable anomaly detection in single-cell transcriptomics data which not only identifies individual anomalies, but also provides a visual explanation based on genes that makes an instance anomalous. This framework has two key ingredients that are not existed in current methods applied in this domain. First, it eliminates the PCA step which is deemed to be an essential component in previous studies. Second, it employs the state-of-art anomaly detector and explainer as the efficient and effective means to find each rare cell and the relevant gene subspace in order to provide explanations for each rare cell as well as the typical normal cell associated with the rare cell's closest normal cells.

</details>


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [2] [Deep Learning Framework for RNA Inverse Folding with Geometric Structure Potentials](https://arxiv.org/abs/2601.00895)
*Annabelle Yao*

Main category: q-bio.QM

TL;DR: 提出结合几何向量感知器(GVP)与Transformer的深度学习框架，用于RNA逆折叠设计，在标准基准和RNA-Puzzles上达到SOTA性能。


<details>
  <summary>Details</summary>
Motivation: RNA的多种生物功能源于其结构多样性，但给定3D构象准确预测和设计RNA序列（逆折叠）仍然具有挑战性。现有方法在序列恢复和结构保真度方面有待改进。

Method: 开发了集成几何向量感知器(GVP)层与Transformer架构的端到端RNA设计框架。使用从BGSU RNA列表过滤和去重后的实验解析RNA 3D结构构建数据集，通过序列恢复率和TM-score分别评估序列和结构保真度。

Result: 在标准基准和RNA-Puzzles上达到最先进性能，恢复率和TM-score分别为0.481和0.332，超越现有方法。使用Rfam注释的掩码家族级验证显示对未见家族的强泛化能力。逆折叠序列经AlphaFold3重折叠后与天然结构高度相似。

Conclusion: GVP层捕获的几何特征显著增强了基于Transformer的RNA设计能力，为RNA逆折叠提供了有效的深度学习解决方案，在序列设计和结构保真度方面均表现出色。

Abstract: RNA's diverse biological functions stem from its structural versatility, yet accurately predicting and designing RNA sequences given a 3D conformation (inverse folding) remains a challenge. Here, I introduce a deep learning framework that integrates Geometric Vector Perceptron (GVP) layers with a Transformer architecture to enable end-to-end RNA design. I construct a dataset consisting of experimentally solved RNA 3D structures, filtered and deduplicated from the BGSU RNA list, and evaluate performance using both sequence recovery rate and TM-score to assess sequence and structural fidelity, respectively. On standard benchmarks and RNA-Puzzles, my model achieves state-of-the-art performance, with recovery and TM-scores of 0.481 and 0.332, surpassing existing methods across diverse RNA families and length scales. Masked family-level validation using Rfam annotations confirms strong generalization beyond seen families. Furthermore, inverse-folded sequences, when refolded using AlphaFold3, closely resemble native structures, highlighting the critical role of geometric features captured by GVP layers in enhancing Transformer-based RNA design.

</details>


### [3] [Comparative Analysis of Formula and Structure Prediction from Tandem Mass Spectra](https://arxiv.org/abs/2601.00941)
*Xujun Che,Xiuxia Du,Depeng Xu*

Main category: q-bio.QM

TL;DR: 该论文系统评估了基于串联质谱预测化合物的计算方法，建立了性能基准并识别了关键瓶颈


<details>
  <summary>Details</summary>
Motivation: LC-MS代谢组学和暴露组学中大部分信号无法通过传统谱库搜索识别，现有谱库远未覆盖LC-MS/MS捕获的化学空间，需要计算方法来预测化合物

Method: 对最先进的预测算法进行系统评估，特别评估了不同加合物类型的分子式预测和结构预测准确性

Result: 建立了现实的性能基准，识别了关键瓶颈，为基于MS的化合物预测改进提供了指导

Conclusion: 该研究为实际应用中选择预测工作流程和识别进一步改进领域提供了系统评估，有助于释放代谢组学和暴露组学的全部潜力

Abstract: Liquid chromatography mass spectrometry (LC-MS)-based metabolomics and exposomics aim to measure detectable small molecules in biological samples. The results facilitate hypothesis-generating discovery of metabolic changes and disease mechanisms and provide information about environmental exposures and their effects on human health. Metabolomics and exposomics are made possible by the high resolving power of LC and high mass measurement accuracy of MS. However, a majority of the signals from such studies still cannot be identified or annotated using conventional library searching because existing spectral libraries are far from covering the vast chemical space captured by LC-MS/MS. To address this challenge and unleash the full potential of metabolomics and exposomics, a number of computational approaches have been developed to predict compounds based on tandem mass spectra. Published assessment of these approaches used different datasets and evaluation. To select prediction workflows for practical applications and identify areas for further improvements, we have carried out a systematic evaluation of the state-of-the-art prediction algorithms. Specifically, the accuracy of formula prediction and structure prediction was evaluated for different types of adducts. The resulting findings have established realistic performance baselines, identified critical bottlenecks, and provided guidance to further improve compound predictions based on MS.

</details>


### [4] [HyperNetWalk: A Unified Framework for Personalized and Population-Level Cancer Driver Gene Identification via Multi-Network Hypergraph Diffusion](https://arxiv.org/abs/2601.01337)
*Xueqing Xu,Yonghang Gao,Duanchen Sun,Ling-Yun Wu*

Main category: q-bio.QM

TL;DR: HyperNetWalk：整合多生物网络和超图扩散的癌症驱动基因识别框架，可在个体和群体层面识别驱动基因


<details>
  <summary>Details</summary>
Motivation: 现有计算方法通常依赖单一生物网络或群体水平突变模式，难以识别患者特异性驱动基因并整合多种网络类型的互补信息

Method: 两阶段框架：第一阶段通过患者特异性子网络上的样本独立随机游走整合PPI网络、基因调控网络和动态共表达网络；第二阶段通过超图随机游走利用跨样本信息同时保留个体突变背景

Result: 在12种TCGA癌症类型上评估显示，HyperNetWalk在个体和群体水平预测中均优于或与最先进方法相当，能高精度识别已知驱动基因并揭示癌症类型特异性驱动基因

Conclusion: 该框架为个体化和群体水平的驱动基因识别提供了统一解决方案，为精准肿瘤学和治疗靶点发现提供了有价值的见解

Abstract: Identifying cancer driver genes is crucial for understanding tumor biology and developing precision therapies. However, existing computational methods often rely on single biological networks or population-level mutation patterns, limiting their ability to identify patient-specific drivers and leverage the complementary information from multiple network types. Here, we present HyperNetWalk, a novel computational framework that integrates multiple biological networks and hypergraph diffusion to identify driver genes at both personalized and cohort levels. In the first stage, HyperNetWalk integrates protein-protein interaction networks, gene regulatory networks, and dynamic co-expression networks through sample-independent random walks on patient-specific subnetworks to capture topological importance and expression perturbation effects. In the second stage, it refines predictions through hypergraph-based random walks that leverage cross-sample information while preserving individual mutational contexts. Comprehensive evaluation on 12 TCGA cancer types demonstrates that HyperNetWalk achieves superior or competitive performance compared to state-of-the-art methods in both personalized and cohort-level predictions. Notably, HyperNetWalk successfully identifies known driver genes with high precision while revealing cancer type-specific drivers that reflect distinct biological mechanisms. Our framework provides a unified solution for personalized and population-based driver gene identification, offering valuable insights for precision oncology and therapeutic target discovery.

</details>


<div id='q-bio.MN'></div>

# q-bio.MN [[Back]](#toc)

### [5] [Allostery Beyond Amplification: Temporal Regulation of Signaling Information](https://arxiv.org/abs/2601.01850)
*Pedro Pessoa,Steve Pressé,S. Banu Ozkan*

Main category: q-bio.MN

TL;DR: 该论文挑战了传统观点，指出变构调节不仅控制酶活性和产物丰度，更重要的是调控信息传递的时序和持续时间，为信号通路提供了时间维度的调控机制。


<details>
  <summary>Details</summary>
Motivation: 传统上认为变构调节主要调控酶活性和产物丰度，但作者认为这种观点不完整。他们旨在探索变构调节在时间维度上的信息传递功能，揭示其在信号通路中的更广泛作用。

Method: 结合随机模型和信息论分析，量化酶调控状态与下游信号组件状态之间的互信息，研究变构调节如何调控信息传递的时序特性。

Result: 发现变构调节不仅控制稳态生产水平，还调控信息传递的时机和持续时间。通过调整信号通路的时间操作机制，变构调节能够从相同的分子组件产生不同的动态结果。

Conclusion: 变构调节为时间信息流、信号特异性和协调提供了物理机制，而不需要改变代谢途径。这扩展了我们对蛋白质调控机制的理解，强调了时间维度在信号传导中的重要性。

Abstract: Allostery is a fundamental mechanism of protein regulation and is commonly interpreted as modulating enzymatic activity or product abundance. Here we show that this view is incomplete. Using a stochastic model of allosteric regulation combined with an information-theoretic analysis, we quantify the mutual information between an enzyme's regulatory state and the states of downstream signaling components. Beyond controlling steady-state production levels, allostery also regulates the timing and duration over which information is transmitted. By tuning the temporal operating regime of signaling pathways, allosteric regulation enables distinct dynamical outcomes from identical molecular components, providing a physical mechanism for temporal information flow, signaling specificity, and coordination without changes in metabolic pathways.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [6] [Toward Auditable Neuro-Symbolic Reasoning in Pathology: SQL as an Explicit Trace of Evidence](https://arxiv.org/abs/2601.01875)
*Kewen Cao,Jianxu Chen,Yongbing Zhang,Ye Zhang,Hongxiao Wang*

Main category: cs.AI

TL;DR: 提出基于SQL的代理框架，通过可执行的SQL查询将细胞特征测量与病理诊断结论连接起来，提高病理图像分析的可解释性和决策可追溯性。


<details>
  <summary>Details</summary>
Motivation: 当前病理图像分析虽然自动化，但临床医生仍不清楚模型决策依据；现有视觉语言模型生成的解释多为相关性描述，缺乏可验证的证据支持。

Method: 1. 提取人类可解释的细胞特征；2. 特征推理代理通过SQL查询在特征表上进行聚合，将视觉证据转化为定量发现；3. 知识比较代理将发现与已有病理知识对比，模拟病理学家从可测量观察到诊断的推理过程。

Result: 在两个病理视觉问答数据集上的实验表明，该方法提高了可解释性和决策可追溯性，同时生成可执行的SQL追踪，将细胞测量与诊断结论联系起来。

Conclusion: SQL中心的代理框架通过可审计的特征测量和推理，为病理图像分析提供了可验证的解释，增强了临床决策的透明度和可信度。

Abstract: Automated pathology image analysis is central to clinical diagnosis, but clinicians still ask which slide features drive a model's decision and why. Vision-language models can produce natural language explanations, but these are often correlational and lack verifiable evidence. In this paper, we introduce an SQL-centered agentic framework that enables both feature measurement and reasoning to be auditable. Specifically, after extracting human-interpretable cellular features, Feature Reasoning Agents compose and execute SQL queries over feature tables to aggregate visual evidence into quantitative findings. A Knowledge Comparison Agent then evaluates these findings against established pathological knowledge, mirroring how pathologists justify diagnoses from measurable observations. Extensive experiments evaluated on two pathology visual question answering datasets demonstrate our method improves interpretability and decision traceability while producing executable SQL traces that link cellular measurements to diagnostic conclusions.

</details>


<div id='stat.ME'></div>

# stat.ME [[Back]](#toc)

### [7] [Beyond P-Values: Importing Quantitative Finance's Risk and Regret Metrics for AI in Learning Health Systems](https://arxiv.org/abs/2601.01116)
*Richik Chakraborty*

Main category: stat.ME

TL;DR: 传统医学证据框架基于随机对照试验和静态置信区间，但AI临床系统会持续学习、适应和演化，需要新的证据评估方法，重点关注校准稳定性、下行风险边界和累积遗憾控制。


<details>
  <summary>Details</summary>
Motivation: AI在临床环境中的部署挑战了传统医学证据框架的基础假设。传统统计方法为固定干预和稳定条件设计，而AI驱动的临床系统会持续学习、适应非平稳环境，其临床危害更多来自校准漂移、罕见严重故障和随时间累积的次优决策。

Method: 借鉴量化金融和在线决策理论中的风险理论概念，提出将自适应AI系统的医学证据重新框架化为时间索引的校准稳定性、有界下行风险和受控累积遗憾。

Result: 提出了一个原则性的数学语言框架，用于评估持续学习下的AI驱动临床系统，为临床实践、研究设计和监管监督提供新的评估维度。

Conclusion: 传统统计显著性概念不足以描述学习型医疗系统中的证据和安全性。新框架不取代随机试验或因果推断，而是通过解决部署后才出现的风险和不确定性维度来补充它们，为AI临床系统的评估提供了更全面的方法。

Abstract: The increasing deployment of artificial intelligence (AI) in clinical settings challenges foundational assumptions underlying traditional frameworks of medical evidence. Classical statistical approaches, centered on randomized controlled trials, frequentist hypothesis testing, and static confidence intervals, were designed for fixed interventions evaluated under stable conditions. In contrast, AI-driven clinical systems learn continuously, adapt their behavior over time, and operate in non-stationary environments shaped by evolving populations, practices, and feedback effects. In such systems, clinical harm arises less from average error rates than from calibration drift, rare but severe failures, and the accumulation of suboptimal decisions over time.
  In this perspective, we argue that prevailing notions of statistical significance are insufficient for characterizing evidence and safety in learning health systems. Drawing on risk-theoretic concepts from quantitative finance and online decision theory, we propose reframing medical evidence for adaptive AI systems in terms of time-indexed calibration stability, bounded downside risk, and controlled cumulative regret. We emphasize that this approach does not replace randomized trials or causal inference, but complements them by addressing dimensions of risk and uncertainty that emerge only after deployment. This framework provides a principled mathematical language for evaluating AI-driven clinical systems under continual learning and offers implications for clinical practice, research design, and regulatory oversight.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [8] [Central Dogma Transformer: Towards Mechanism-Oriented AI for Cellular Understanding](https://arxiv.org/abs/2601.01089)
*Nobuyuki Ota*

Main category: cs.LG

TL;DR: CDT是一个整合DNA、RNA和蛋白质预训练语言模型的架构，遵循中心法则方向逻辑，通过交叉注意力机制产生统一虚拟细胞嵌入，在CRISPRi增强子扰动数据上验证有效。


<details>
  <summary>Details</summary>
Motivation: 理解细胞机制需要整合DNA、RNA和蛋白质信息，但现有的领域特定基础模型各自孤立，限制了整合细胞过程建模能力。

Method: 提出中心法则变换器（CDT），整合DNA、RNA和蛋白质预训练语言模型，采用方向性交叉注意力机制：DNA-to-RNA注意力建模转录调控，RNA-to-Protein注意力建模翻译关系，产生统一虚拟细胞嵌入。

Result: 在K562细胞的CRISPRi增强子扰动数据上验证CDT v1，获得Pearson相关系数0.503，达到跨实验变异性理论上限（r=0.797）的63%。注意力分析和梯度分析提供互补解释窗口。

Conclusion: 与生物信息流对齐的AI架构既能实现预测准确性，又能获得机制可解释性，为整合多模态细胞建模提供了有前景的方向。

Abstract: Understanding cellular mechanisms requires integrating information across DNA, RNA, and protein - the three molecular systems linked by the Central Dogma of molecular biology. While domain-specific foundation models have achieved success for each modality individually, they remain isolated, limiting our ability to model integrated cellular processes. Here we present the Central Dogma Transformer (CDT), an architecture that integrates pre-trained language models for DNA, RNA, and protein following the directional logic of the Central Dogma. CDT employs directional cross-attention mechanisms - DNA-to-RNA attention models transcriptional regulation, while RNA-to-Protein attention models translational relationships - producing a unified Virtual Cell Embedding that integrates all three modalities. We validate CDT v1 - a proof-of-concept implementation using fixed (non-cell-specific) RNA and protein embeddings - on CRISPRi enhancer perturbation data from K562 cells, achieving a Pearson correlation of 0.503, representing 63% of the theoretical ceiling set by cross-experiment variability (r = 0.797). Attention and gradient analyses provide complementary interpretive windows: in detailed case studies, these approaches highlight largely distinct genomic regions, with gradient analysis identifying a CTCF binding site that Hi-C data showed as physically contacting both enhancer and target gene. These results suggest that AI architectures aligned with biological information flow can achieve both predictive accuracy and mechanistic interpretability.

</details>


### [9] [Edge-aware GAT-based protein binding site prediction](https://arxiv.org/abs/2601.02138)
*Weisen Yang,Hanqing Zhang,Wangren Qiu,Xuan Xiao,Weizhong Lin*

Main category: cs.LG

TL;DR: 提出Edge-aware GAT模型，用于精细预测蛋白质结合位点，通过原子级图结构和多维特征整合，在基准数据集上达到0.93 ROC-AUC，优于现有方法。


<details>
  <summary>Details</summary>
Motivation: 准确识别蛋白质结合位点对理解生物分子相互作用机制和药物靶点设计至关重要。传统方法在平衡预测精度与计算效率方面存在困难，特别是在捕捉复杂空间构象时。

Method: 提出Edge-aware GAT模型，构建原子级图结构，整合几何描述符、DSSP二级结构、相对溶剂可及性等多维特征。通过将原子间距离和方向向量作为注意力机制中的边特征，增强模型表示能力。使用方向张量传播和残基级注意力池化进一步改进结合位点定位。

Result: 在基准数据集上，模型在蛋白质-蛋白质结合位点预测中达到0.93 ROC-AUC，优于多种最先进方法。PyMOL可视化证实了模型的实用性和可解释性。已部署公开可访问的Web服务器。

Conclusion: 该方法为识别蛋白质功能位点提供了新颖高效的解决方案，平衡了预测精度、泛化能力和可解释性。

Abstract: Accurate identification of protein binding sites is crucial for understanding biomolecular interaction mechanisms and for the rational design of drug targets. Traditional predictive methods often struggle to balance prediction accuracy with computational efficiency when capturing complex spatial conformations. To address this challenge, we propose an Edge-aware Graph Attention Network (Edge-aware GAT) model for the fine-grained prediction of binding sites across various biomolecules, including proteins, DNA/RNA, ions, ligands, and lipids. Our method constructs atom-level graphs and integrates multidimensional structural features, including geometric descriptors, DSSP-derived secondary structure, and relative solvent accessibility (RSA), to generate spatially aware embedding vectors. By incorporating interatomic distances and directional vectors as edge features within the attention mechanism, the model significantly enhances its representation capacity. On benchmark datasets, our model achieves an ROC-AUC of 0.93 for protein-protein binding site prediction, outperforming several state-of-the-art methods. The use of directional tensor propagation and residue-level attention pooling further improves both binding site localization and the capture of local structural details. Visualizations using PyMOL confirm the model's practical utility and interpretability. To facilitate community access and application, we have deployed a publicly accessible web server at http://119.45.201.89:5000/. In summary, our approach offers a novel and efficient solution that balances prediction accuracy, generalization, and interpretability for identifying functional sites in proteins.

</details>


<div id='stat.AP'></div>

# stat.AP [[Back]](#toc)

### [10] [Model-Assisted Causal Inference for the Treatment Effect on Recurrent Events in the Presence of Terminal Events](https://arxiv.org/abs/2601.01245)
*Yiyuan Huang,Ling Zhou,Min Zhang,Peter X. K. Song*

Main category: stat.AP

TL;DR: 提出PR-MSMaT方法，解决在存在终末事件时评估机械循环支持设备对复发性事件风险的治疗效果，克服现有方法在时间变化事件率下的局限性。


<details>
  <summary>Details</summary>
Motivation: 评估终末期心衰患者接受机械循环支持设备的获益，现有方法在存在终末事件时存在生存时间偏倚问题，且当复发性事件率随时间变化时，WA检验会出现I类错误膨胀。

Method: 提出比例率边际结构模型辅助检验（PR-MSMaT），在可分离治疗效果的因果推断框架下处理复发性事件和终末事件，适用于时间变化的复发性事件率。

Result: 模拟研究表明PR-MSMaT能适当控制I类错误，同时在时间变化的复发性事件率下获得与WA检验相当的检验功效。

Conclusion: PR-MSMaT方法填补了方法学空白，成功应用于比较不同MCS设备在术后胃肠道出血风险中的差异，为存在终末事件和时间变化事件率的治疗效果评估提供了可靠工具。

Abstract: This paper is motivated by evaluating the benefits of patients receiving mechanical circulatory support (MCS) devices in end-stage heart failure management inference, in which hypothesis testing for a treatment effect on the risk of recurrent events is challenged in the presence of terminal events. Existing methods based on cumulative frequency unreasonably disadvantage longer survivors as they tend to experience more recurrent events. The While-Alive-based (WA) test has provided a solution to address this survival-length-bias problem, and it performs well when the recurrent event rate holds constant over time. However, if such a constant-rate assumption is violated, the WA test can exhibit an inflated type I error and inaccurate estimation of treatment effects. To fill this methodological gap, we propose a Proportional Rate Marginal Structural Model-assisted Test (PR-MSMaT) in the causal inference framework of separable treatment effects for recurrent and terminal events. Using the simulation study, we demonstrate that our PR-MSMaT can properly control type I error while gaining power comparable to the WA test under time-varying recurrent event rates. We employ PR-MSMaT to compare different MCS devices with the postoperative risk of gastrointestinal bleeding among patients enrolled in the Interagency Registry of Mechanically Assisted Circulatory Support program.

</details>
